Zymeworks is a clinical-stage biotechnology company unlocking new possibilities in cancer and autoimmune disease treatment. The company thrives on scientific challenges to deliver transformational therapies for patients with difficult-to-treat cancers and other serious diseases through its pipeline of novel multifunctional therapeutics.
| Ownership Public Company |
| Stock ZYME (Nasdaq) |
Zymeworks Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of multifunctional biotherapeutics for the treatment of cancer and other
Zymeworks focuses on the discovery, development, and commercialization of novel, multifunctional biotherapeutics using clinically validated platforms for antibody-drug conjugates and multispecific antibody therapeutics.
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Connect with Zymeworks Inc.